kabutan

KYORIN Pharmaceutical Co.,Ltd.(4569) Summary

4569
TSE Prime
KYORIN Pharmaceutical Co.,Ltd.
1,543
JPY
+20
(+1.31%)
Aug 1, 3:30 pm JST
10.24
USD
Aug 1, 2:30 am EDT
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
18.4
PBR
0.65
Yield
3.69%
Margin Trading Ratio
68.88
Stock Price
Aug 1, 2025
Opening Aug 1, 9:00 am
1,546 JPY 10.25 USD
Previous Close Jul 31
1,523 JPY 10.23 USD
High Aug 1, 9:00 am
1,558 JPY 10.33 USD
Low Aug 1, 9:07 am
1,532 JPY 10.15 USD
Volume
149,000
Trading Value
0.23B JPY 1.53M USD
VWAP
1544.43 JPY 10.26 USD
Minimum Trading Value
154,300 JPY 1,024 USD
Market Cap
0.09T JPY 0.62B USD
Number of Trades
462
Liquidity & Number of Trades
As of Aug 1, 2025
Liquidity
Mid
1-Year Average
342
1-Year High Mar 5, 2025
5,734
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jul 25, 2025 9,800 136,700 13.95
Jul 18, 2025 10,000 142,400 14.24
Jul 11, 2025 12,500 155,300 12.42
Jul 4, 2025 15,600 156,000 10.00
Jun 27, 2025 22,700 144,500 6.37
Company Profile
KYORIN Pharmaceutical Co., Ltd. is a mid-tier pharmaceutical company. Its main products include asthma medications and expectorants. The company also produces generic drugs and gastrointestinal medicines.
Sector
Pharmaceuticals
KYORIN Pharmaceutical Co., Ltd. primarily engages in the manufacture and sale of pharmaceuticals. The company focuses on prescription drugs such as asthma medications and expectorants, while also having a track record in generic drugs and COVID-19 detection reagents. With manufacturing and sales companies within its group, KYORIN has established an integrated business structure. The company procures some pharmaceutical raw materials from its affiliated companies. In recent years, KYORIN has undergone group restructuring, including the absorption and merger of wholly-owned subsidiaries, to improve management efficiency and accelerate decision-making processes. While adapting to changing medical needs, the company is also concentrating on developing new drugs using its proprietary drug discovery technologies.